NasdaqGS:DRNA

Stock Analysis Report

Executive Summary

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals.


Snowflake Analysis

Flawless balance sheet and slightly overvalued.

Share Price & News

How has Dicerna Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DRNA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.0%

DRNA

-2.5%

US Biotechs

-7.6%

US Market


1 Year Return

66.4%

DRNA

8.9%

US Biotechs

10.2%

US Market

Return vs Industry: DRNA exceeded the US Biotechs industry which returned 6.5% over the past year.

Return vs Market: DRNA exceeded the US Market which returned 10.5% over the past year.


Shareholder returns

DRNAIndustryMarket
7 Day-1.0%-2.5%-7.6%
30 Day2.1%2.8%-4.5%
90 Day-15.5%2.2%-0.6%
1 Year66.4%66.4%9.8%8.9%12.5%10.2%
3 Year570.6%570.6%17.5%14.4%37.1%28.3%
5 Year-19.7%-19.7%-1.5%-6.0%60.8%43.2%

Price Volatility Vs. Market

How volatile is Dicerna Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Dicerna Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: DRNA ($20.4) is trading below our estimate of fair value ($72.4)

Significantly Below Fair Value: DRNA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: DRNA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: DRNA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DRNA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DRNA is overvalued based on its PB Ratio (10.4x) compared to the US Biotechs industry average (3x).


Next Steps

Future Growth

How is Dicerna Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

-0.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DRNA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DRNA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DRNA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: DRNA's revenue (16.8% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: DRNA's revenue (16.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DRNA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Dicerna Pharmaceuticals performed over the past 5 years?

-15.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DRNA is currently unprofitable.

Growing Profit Margin: DRNA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DRNA is unprofitable, and losses have increased over the past 5 years at a rate of -15% per year.

Accelerating Growth: Unable to compare DRNA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DRNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (66.2%).


Return on Equity

High ROE: DRNA has a negative Return on Equity (-73.98%), as it is currently unprofitable.


Next Steps

Financial Health

How is Dicerna Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: DRNA's short term assets ($320.4M) exceed its short term liabilities ($119.4M).

Long Term Liabilities: DRNA's short term assets ($320.4M) exceed its long term liabilities ($82.5M).


Debt to Equity History and Analysis

Debt Level: DRNA is debt free.

Reducing Debt: DRNA had no debt 5 years ago.


Balance Sheet

Inventory Level: DRNA has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if DRNA's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable DRNA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: DRNA is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 22.8% per year.


Next Steps

Dividend

What is Dicerna Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DRNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate DRNA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DRNA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DRNA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DRNA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Douglas Fambrough (50yo)

9.8yrs

Tenure

US$2,497,561

Compensation

Dr. Douglas M. Fambrough, III, Ph.D., is a Co-Founder Dicerna Pharmaceuticals, Inc. and has been its Chief Executive Officer and President since May 2010. Dr. Fambrough served as a Venture Partner at Oxfor ...


CEO Compensation Analysis

Compensation vs Market: Douglas's total compensation ($USD2.50M) is below average for companies of similar size in the US market ($USD3.92M).

Compensation vs Earnings: Douglas's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Douglas Fambrough
Co-Founder9.8yrsUS$2.50m0.018% $249.9k
John Green
Chief Financial Officer3.8yrsUS$1.25m0.028% $394.6k
Bob Brown
Executive VP of Research & Development and Chief Scientific Officer8.1yrsUS$1.29m0.0073% $101.6k
Mark Behlke
Co-Founder & Member of Scientific Advisory Board0yrsno datano data
John Rossi
Co-Founder & Chairman of Scientific Advisory Board11.3yrsno datano data
James Weissman
Executive VP & COO0.4yrsUS$1.36m0.032% $444.1k
Regina Paglia
Senior Vice President of Human Resources1yrsno datano data
David Miller
Senior Vice President of Corporate Operations & Alliance Management0.4yrsno datano data
Jennifer Lockridge
Senior Vice President of Program Development2.1yrsno datano data
Ralf Rosskamp
Chief Medical Officer2.7yrsUS$953.29k0.0052% $72.4k

2.4yrs

Average Tenure

61yo

Average Age

Experienced Management: DRNA's management team is considered experienced (2.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Douglas Fambrough
Co-Founder9.8yrsUS$2.50m0.018% $249.9k
Mark Behlke
Co-Founder & Member of Scientific Advisory Board0yrsno datano data
John Rossi
Co-Founder & Chairman of Scientific Advisory Board11.3yrsno datano data
J. Buchi
Independent Chairman of the Board1.1yrsUS$272.82kno data
Stephen Hoffman
Independent Director12.3yrsUS$272.39kno data
Frank McCormick
Member of Scientific Advisory Board11.3yrsno datano data
Adam Koppel
Independent Director2.8yrsUS$260.14kno data
Martin Freed
Independent Director3.7yrsUS$265.63kno data
Cynthia Smith
Independent Director1.5yrsUS$269.96kno data
Patrick Gray
Independent Director0.4yrsno datano data

3.7yrs

Average Tenure

61yo

Average Age

Experienced Board: DRNA's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: DRNA insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 45.5%.


Top Shareholders

Company Information

Dicerna Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Dicerna Pharmaceuticals, Inc.
  • Ticker: DRNA
  • Exchange: NasdaqGS
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.391b
  • Shares outstanding: 68.43m
  • Website: https://www.dicerna.com

Number of Employees


Location

  • Dicerna Pharmaceuticals, Inc.
  • 87 Cambridgepark Drive
  • Cambridge
  • Massachusetts
  • 2140
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DRNANasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJan 2014
DPLDB (Deutsche Boerse AG)YesCommon StockDEEURJan 2014

Biography

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Its principal development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company’s development programs also comprise additional rare disease programs; a program for the treatment of hypercholesterolemia; and various programs in various therapeutic areas involving liver function. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/27 01:51
End of Day Share Price2020/02/26 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.